FGFR3 mutation/fusion
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-FGFR3-MUTATION |
|---|---|
| Type | Biomarker |
| Aliases | Мутація/фузія FGFR3 |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | None declared |
Biomarker Facts
| Biomarker type | gene_mutation |
|---|---|
| Mutation details | {"functional_impact": "Constitutive FGFR3 signaling", "gene": "FGFR3", "hotspots": ["S249C", "Y373C", "G370C", "R248C"], "type": "activating"} |
| Measurement | MethodTumor-tissue NGS OR ctDNA OR allele-specific PCR Sensitivity requirementStandard NGS |
| Related biomarkers | None declared |
Notes
Required pre-erdafitinib testing.
Used By
Actionability
BMA-FGFR3-MUTATION-MM- In multiple myeloma, t(4;14) translocation places MMSET/FGFR3 under IgH control; ~30% of...BMA-FGFR3-R248C-UROTHELIAL- FGFR3 R248C is an extracellular-domain activating mutation included in the erdafitinib co...BMA-FGFR3-S249C-UROTHELIAL- FGFR3 S249C is the most common activating FGFR3 mutation in urothelial carcinoma. Erdafit...BMA-FGFR3-TACC3-UROTHELIAL- FGFR3-TACC3 fusion is an activating rearrangement in urothelial carcinoma (~2-3%). Includ...BMA-FGFR3-Y373C-UROTHELIAL- FGFR3 Y373C is a transmembrane-domain activating mutation in urothelial carcinoma; includ...
Biomarker
BIO-FGFR1- FGFR1 alterations (amplification / mutation / fusion)BIO-FGFR2- FGFR2 alterations (fusion / amplification / mutation)
Indications
IND-UROTHELIAL-2L-ERDAFITINIB- IND-UROTHELIAL-2L-ERDAFITINIB
Red flag
RF-UROTHELIAL-HIGH-RISK-BIOLOGY- FGFR3 mutation/fusion — opens erdafitinib (THOR) pathway.